Oncologist
Published

A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.

Authors

Kuei-Ting Chen, Russell Madison, Jay Moore, Dexter Jin, Zoe Fleischmann, Justin Newberg, Alexa Schrock, Neeru Bhardwaj, Katherine T Lofgren, Jie He, Garrett Frampton, Priti Hegde, David Fabrizio, Michael J Pishvaian, Ericka Ebot, Aatur Singhi, Ethan Sokol
Read More

Abstract

Pancreatic cancer (PC) represents an aggressive disease with median overall survival (OS) of less than 1 year in the front-line setting. FOLFIRINOX and gemcitabine and paclitaxel (GP) are standard of care options for these patients; however, optimal selection of therapy is challenging.

PMID:37354528 | DOI:

UK DRI Authors

Jay Moore

Research Assistant

Mapping cell-type-specific vulnerability by integrating large-scale genomic and neuropathological data.

Jay Moore